Name: Tenofovir Alafenamide
Price: 295.00 USD

- Overview
  - Tenofovir alafenamide is an antiretroviral developed by Gilead and the anti-HIV activity was reported in 1993. It is an investigational precursor to Tenovor, a nucleotide reverse transcriptase inhibitor. Tenofovir alafenamide is more efficient at delivering Tenofovir to target cells.
    
    Please contact us at for specific academic pricing.
    
    Background
    
    Tenofovir alafenamide is a nucleotide analog reverse transcriptase inhibitor that terminates DNA transcription.
- Properties
  - CAS Number
    
    379270-37-8
    
    Molecular Formula
    
    C21H29N6O5P
    
    Molecular Weight
    
    476.47
    
    Appearance
    
    White or off-white powder
    
    Solubility
    
    freely soluble in methanol,soluble in ethanol and DMSO, sparingly soluble in water.
    
    Other Properties
    
    Source: Synthetic
    Purity Level: 98% - 102% (on anhydrous basis)
    
    Storage
    
    -20°C
    
    * For research use only
- Applications
  - Application Description
    
    Spectrum: antiretroviral
    
    Eukaryotic Cell Culture Applications: Tenofovir alafenamide is 1000- and 10-fold more active against HIV in vitro than Tenofovir or tenofovir disoproxil fumarate, respectively, and the compound is stable in biological matrices (Ray et al, 2016).It reduces HIV-1 viral replication in MT-2 cells with an EC50 value of 5 nM (Ray et al, 2016). During in vitro studies with activated or resting peripheral blood mononuclear cells, MT2 and Jerkat T-cell lines, authors found that Tenofovir alafenamide did not inhibit mitochondrial DNA synthesis (Stray et al, 2017).